Bioactive Products
| A unique collection of 674 anticancer natural compounds for high throughput screening (HTS) and New anticancer drug research | ||
| Catalog No: | B91 | Anticancer Compound Library Screening Details |
| Size: | 1mg/well * 674 Compounds 2mg/well * 674 Compounds | |
| Cat. No. | Information |
| CFN97318 | 3-Oxo-24,25,26,27-tetranortirucall-7-en-23,21-olide 3-Oxo-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone shows significant inhibitory activities against human cancer cell lines in vitro. |
| CFN97326 | Stigmasterol Stigmasterol is used as a precursor in the manufacture of synthetic progesterone, it is an antagonist of the bile acid nuclear receptor FXR, which has anti-inflammatory, thyroid inhibitory, cholesterol-lowering, antiperoxidative and hypoglycemic effects; it has indicated that stigmasterol may be useful in prevention of certain cancers, including ovarian, prostate, breast, and colon cancers. Stigmasterol inhibits the NF-kappaB pathway. |
| CFN97339 | Rocaglamide Rocaglamides are potent natural anticancer products that inhibit proliferation of various cancer cells at nanomolar concentrations, it prevents tumor growth and sensitize resistant cancer cells to apoptosis by blocking the MEK-ERK-eIF4 pathway. Rocaglamides can suppress the PMA-induced expression of NF-kappaB target genes and sensitize leukemic T cells to apoptosis induced by TNFalpha, cisplatin, and gamma-irradiation, suggests that rocaglamide derivatives could serve as lead structures in the development of anti-inflammatory and tumoricidal drugs. Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas. |
| CFN97402 | Eriocalyxin B Eriocalyxin B induces apoptosis and cell cycle arrest in pancreatic adenocarcinoma cells through caspase- and p53-dependent pathways, should be considered a candidate for pancreatic cancer treatment; it is a specific inhibitor of STAT3, it directly targets STAT3 through a covalent linkage to inhibit the phosphorylation and activation of STAT3 and induces apoptosis of STAT3-dependent tumor cells. Eriocalyxin B exerts potent antiinflammatory effects through selective modulation of pathogenic Th1 and Th17 cells by targeting critical signaling pathways. Eriocalyxin B reversibly interfer with the binding of p65 and p50 subunits to the DNA in a noncompetitive manner. |
| CFN97409 | Chinensine B Chinensine B and Chinensines A, C, D and Ε are antitumor diterpenoids. |
